Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (5241)	1/13/2010 1:54:34 PM
From: Jibacoa	Respond to of 7424

CYTXW Was up 16.77% earlier, but is up only 8.38% at present <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (5241)	2/12/2012 11:51:30 PM
From: Jibacoa	Respond to of 7424

PCYC was up 17.34% and continued doing OK AHs Volume of 3,936,511 was >2x its ADV On Feb9 it reported that its net income for the 2ndQ was $58.6 M ( $0.82/shr) vs. a loss of $6.1M ( $0.10'shr), for the 2ndQ in 2010 <g> The cash available as of Dec31 was $240.3 M vs. $112.3 M as of Jun 30 In Dec, it entered into a collaboration with Janssen Biotech, a subsidiary of JNJ, to develop PCI-32765, a Bruton's Tyrosine Kinase (BTK) inhibitor, being developed for the treatment of NHL, CLL and MM. PCYC received upfront payments of $150M and is expected to receive an additional $825M based on certain milestones. <g> bigcharts.marketwatch.com Bernard